Acquisitions, Distributions, Partnerships, and Recognitions - Research Reports on Dr Pepper Snapple, AmericanTower, Allergan, Zoetis and Aetna

NEW YORK, September 25, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Dr Pepper Snapple Group, Inc. (NYSE: DPS), American Tower Corporation (NYSE: AMT), Allergan Inc. (NYSE: AGN), Zoetis Inc. (NYSE: ZTS) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6743-100free.

--
Dr Pepper Snapple Group, Inc. Research Reports
On September 3, 2014, Dr Pepper Snapple Group, Inc. (Dr Pepper Snapple) reported the signing of a non-binding letter of intent for acquiring the business assets of Davis Beverage Group and Davis Bottling Co. (Davis). The Company stated that the acquisition, if completed, would include most of Davis' direct store delivery territory in Pennsylvania, a portion of its New Jersey territory, and its production and distribution facilities, delivery vehicles, vending equipment, among other assets. The transaction is expected to be completed in Q4 2014. Commenting on the proposed acquisition, Larry Young, President and CEO of Dr Pepper Snapple, said, "Davis has proudly served customers and consumers for more than 70 years and been a great partner to us both as a distributor of our brands and as a contract manufacturer. We're excited about the possibility of building on their great heritage while nearly doubling our direct store delivery footprint in Pennsylvania and adding their glass bottling capabilities." The full research reports on Dr Pepper Snapple are available to download free of charge at:

http://www.analystsreview.com/Sep-25-2014/DPS/report.pdf

--
American Tower Corporation Research Reports
On September 10, 2014, American Tower Corporation (American Tower) announced that its board of directors has declared a $0.36 per share of quarterly cash distribution on the Company's common stock, payable on October 7, 2014 to stockholders of record at the close of business on September 23, 2014. The board also declared a cash distribution of c. $1.31 per share on the Company's 5.25% Mandatory Convertible Preferred Stock, Series A, payable on November 17, 2014 to stockholders of record at the close of business on November 1, 2014. The full research reports on American Tower are available to download free of charge at:

http://www.analystsreview.com/Sep-25-2014/AMT/report.pdf

--
Allergan Inc. Research Reports
On September 18, 2014, Allergan Inc. (Allergan) reported that Kyle Richards, a TV personality, fashion entrepreneur and star of the "Real Housewives of Beverly Hills," is partnering with the Company to increase awareness about Chronic Dry Eye. The Company stated that Richards was diagnosed with a type of Chronic Dry Eye disease and was prescribed RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, which is manufactured by the Company. According to Allergan, RESTASIS® is the first and only prescription medicine approved by the U.S. Food and Drug Administration that helps eyes' natural ability to produce tears. Sharing her experience, Richards stated, "A few years ago, during the filming of the 'Housewives' first season, I began to notice that my eyes were bothering me throughout the day." She added, "I was surprised to find out that my eyes were not producing enough tears, and I had Chronic Dry Eye disease. My doctor prescribed RESTASIS® for me, and after using it daily for six months, I noticed I was making more of my own tears." The full research reports on Allergan are available to download free of charge at:

http://www.analystsreview.com/Sep-25-2014/AGN/report.pdf

--
Zoetis Inc. Research Reports
On September 16, 2014, Zoetis Inc. (Zoetis) announced that it has been included in the top 10 on Working Mother magazine's "100 Best Companies for Working Mothers" list, which selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs. Roxanne Lagano, Executive Vice President and Chief Human Resources Officer at Zoetis, stated, "Zoetis is honored to be named one of Working Mother magazine's top ten companies in our first year as an independent public company. In establishing Zoetis, we have built a culture that truly supports our people and recognizes their importance. This means we are committed to the success of working mothers at Zoetis and provide a range of benefits and family-friendly policies to foster a supportive working environment for all our colleagues." Zoetis will be recognized at the Working Mother 100 Best Companies Gala Awards Dinner on October 15, 2014 in New York City, and will be featured in the Working Mother magazine's October/November issue. The full research reports on Zoetis are available to download free of charge at:

http://www.analystsreview.com/Sep-25-2014/ZTS/report.pdf

--
Aetna Inc. Research Reports
On September 19, 2014, Aetna Inc. (Aetna) reported that a quarterly common stock cash dividend of $0.225 per share has been declared by the board, payable on October 31, 2014 to shareholders of record at the close of business on October 16, 2014. The full research reports on Aetna are available to download free of charge at:

http://www.analystsreview.com/Sep-25-2014/AET/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review